Half Year 2025 Fisher & Paykel Healthcare Corporation Ltd Earnings Call Transcript
Key Points
- Fisher & Paykel Healthcare Corp Ltd (FSPKF) reported an 18% increase in operating revenue for the first half of the 2025 financial year, reaching $951 million.
- Net profit after tax rose by 43% to $153 million, indicating strong financial performance.
- The company successfully launched new products, including the 950 system and Airvo 3 in the US, contributing to momentum in the hospital business.
- The manufacturing site in Guangzhou is now operational, enhancing production capabilities.
- Gross margin improved to 61.9%, up 141 basis points from the previous year, driven by overhead efficiency and margin improvement efforts.
- Foreign currency movements negatively impacted net profit after tax by $2.7 million compared to the same period last year.
- The guidance for the second half remains uncertain due to the unpredictable nature of seasonal hospitalizations, including the impact of COVID, flu, and RSV.
- Operating expenses grew by 11%, which could pressure margins if revenue growth does not keep pace.
- The impact of tariffs and geopolitical tensions, particularly between the US and Mexico, remains a concern for future operations.
- Freight rates, currently a tailwind, are expected to become a headwind in the next financial year, potentially affecting margins.
Welcome to Fisher & Paykel Healthcare's results conference call. My name is Karen, and I'll be your operator for today's call. (Operator Instructions) Please note this conference call is being recorded.
I would now like to turn the call over to Marcus Driller, VP Corporate.
Thank you, Karen. Good morning, everyone, and welcome to the conference call for Fisher & Paykel Healthcare's first-half results for the 2025 financial year. On the call today are Lewis Gradon, our Managing Director and Chief Executive Officer; Lyndal York, Chief Financial Officer; and Andrew Somerville, our VP of Products and Technology.
Lewis and Lyndal will first provide an overview of the results and then we'll move on to questions. We'll be discussing our results for the six months ended September 30, 2024. Earlier today, we provided our 2025 interim report including financial statements and commentary on our results to the NZX and ASX. These disclosures can be accessed
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
